首页> Blood: The Journal of the American Society of Hematology> Disease Burden Subgroup Analysis of HealthRelated Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study ( TOWER)

Disease Burden Subgroup Analysis of HealthRelated Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study ( TOWER)

导出原文传递

翻译打印收藏纠错

第一作者： Stein, Anthony S.

作者： Stein, Anthony S. ^[1] ; Zimmerman, Zachary F. ^[2] ; Cannell, Paul ^[3] ; Dombret, Herve ^[4] ; Maertens, Johan ^[5] ; Topp, Max S. ^[6] ; Franklin, Janet L. ^[7] ; Cong, Ze ^[8] ; Zhang, Xinke ^[9] ; Li, Yan ^[10] ; Schuh, Andre ^[11]

作者单位： Amgen Inc, Global Dev, Thousand Oaks, CA 91320 USA ^[1] Fiona Stanley Hosp, Perth, WA, Australia ^[2] Amgen Inc, Thousand Oaks, CA 91320 USA ^[3] City Hope Natl Med Ctr, Dept Hematol Malignancies Translat Sci, Gehr Family Ctr Leukemia Res ^[4] Univ Ziekenhuis Leuven, Dept Hematol, Leuven, Belgium ^[5] Amgen Inc, Global Hlth Econ, San Francisco, CA USA ^[6] Univ Florida, Coll Pharm, Gainesville, FL USA ^[7] Univ Paris Diderot, Hop St Louis, Hematol, Paris, France ^[8] Amgen Inc, Global Hlth Econ, Thousand Oaks, CA 91320 USA ^[9] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada ^[10] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany ^[11]

发布时间 2020-08-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交